Oculis CEO Riad Sherif, who once worked for Novartis and Alcon, reveals which company he’d invest in following the spin-off of the latter from the former – but mostly about the Switzerland-based start-up’s promising new pipeline for DME, post-surgery inflammation, and dry eye.